# Nuclide record prostate-mhspc (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/prostate-mhspc/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "prostate-mhspc" ;
  schema:name "Metastatic hormone-sensitive prostate cancer"@en ;
  schema:alternateName "mHSPC"@en, "Metastatic castration-sensitive prostate cancer"@en, "mCSPC"@en, "De novo metastatic prostate cancer"@en, "Hormone-naive metastatic prostate cancer"@en ;
  schema:description "Metastatic hormone-sensitive prostate cancer is disease that has spread but still responds to lowering testosterone. Hormone therapy alone is no longer enough: adding an androgen receptor inhibitor, and docetaxel for high-volume disease, lengthens life by years."@en ;
  schema:url <https://nuclide.cc/indications/prostate-mhspc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Prostate_cancer#Metastatic_disease> ;
  schema:citation <https://en.wikipedia.org/wiki/Prostate_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> ;
  nuclide:tag "subtype-page" ;
  nuclide:related <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/indications/prostate-nmcrpc/>, <https://nuclide.cc/indications/prostate-bcr/>, <https://nuclide.cc/indications/prostate-high-risk/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/trials/psmaddition/>, <https://nuclide.cc/technologies/psma-pet/> ;
  nuclide:standardOfCare <https://nuclide.cc/drugs/abiraterone/>, <https://nuclide.cc/drugs/enzalutamide/>, <https://nuclide.cc/trials/stampede/>, <https://nuclide.cc/drugs/docetaxel/>, <https://nuclide.cc/drugs/abiraterone/>, <https://nuclide.cc/trials/chaarted/>, <https://nuclide.cc/trials/stampede/>, <https://nuclide.cc/terms/oligometastatic/>, <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/trials/psmaddition/> .